MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/trf.70056

Медицинская библиотека · Transfusion · 2025

Antenatal risk estimation for exchange transfusions in neonates with hemolytic disease of the fetus and newborn in a changing treatment landscape: A multicenter, retrospective cohort study.

de Winter Derek P, de Haas Masja, Hulzebos Christian V, Lukens Michaël V, Prins Sandra A, Been Jasper V, d'Haens Esther J, Vijlbrief Daniël C, Vrancken Sabine L A G, Trompenaars Amanda M P, Ceelie Huib, van Zogchel Lieke M J, Joosen Annemiek M C P, Meijssen Clemens B, van Hillegersberg J L A M, Zant Janneke C, van Rossem Maaike C, van Beek Ron, Stas Helene G, Counsilman Clare E, Knol F R, Schiering I A M, Dubbink-Verheij Gerdina H, Verweij E J T, Lopriore Enrico, WISE investigators

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Neonates with hemolytic disease of the fetus and newborn (HDFN) may require exchange transfusions (ET) for severe hyperbilirubinemia. We evaluated if ET in neonates with HDFN was associated with the maximum maternal titer and antibody-dependent cellular cytotoxicity (ADCC) and we determined the change in the number of hospitals performing ET in the Netherlands.

STUDY DESIGN AND

METHODS

National, multicenter analysis of neonates for whom an ET product (c.q. reconstituted whole blood) was ordered between Jan 1, 2011 and Dec 31, 2021 in the Netherlands. To quantify the ET risk, we retrieved maternal serological test results for cases with an ET for non-ABO HDFN (numerator) and from all alloimmunized pregnancies (denominator). Current and past ET practices were assessed with a questionnaire.

RESULTS

Twenty-four participating centers ordered 1564 of the total 1824 (84%) ET products in the 11-year study period. We identified 627 patients for whom a product was ordered, among these 111 (17.7%) received ET for HDFN. We found increasing ET rates in D-mediated HDFN from 0.9% (5/558) when maximum titers were ≤ 1:32 to 19.6% (18/92) if titers were 1:512. Rates of ET increased from 1.1% (9/823) if the maximum ADCC was <50% to 18.7% (72/386) if the ADCC was ≥50%. The number of hospitals practicing ET nowadays was 36.7% (18/49), a 56.1% decline compared to before 2010 (41/49).

DISCUSSION: Antenatal serological tests may aid caregivers to anticipate the need for ET in neonates with non-ABO HDFN. We found a substantially altered treatment landscape with considerably fewer Dutch hospitals performing ET.

Для цитирования: de Winter Derek P, de Haas Masja, Hulzebos Christian V, Lukens Michaël V, Prins Sandra A, Been Jasper V, d'Haens Esther J, Vijlbrief Daniël C, Vrancken Sabine L A G, Trompenaars Amanda M P, Ceelie Huib, van Zogchel Lieke M J, Joosen Annemiek M C P, Meijssen Clemens B, van Hillegersberg J L A M, Zant Janneke C, van Rossem Maaike C, van Beek Ron, Stas Helene G, Counsilman Clare E, Knol F R, Schiering I A M, Dubbink-Verheij Gerdina H, Verweij E J T, Lopriore Enrico, WISE investigators. Antenatal risk estimation for exchange transfusions in neonates with hemolytic disease of the fetus and newborn in a changing treatment landscape: A multicenter, retrospective cohort study.. Transfusion. 2025. DOI: 10.1111/trf.70056.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.